CRL Intrinsic Stock Value – Investors in Charles River Laboratories International Urged to Take Action Before Deadline Set by The Schall Law Firm
June 19, 2023
🌥️Trending News
Charles River Laboratories ($NYSE:CRL) International, Inc. (NYSE: CRL) is a leading provider of laboratory animal and research services to the global pharmaceutical, biotechnology, medical device and contract research organizations (CROs). The company is committed to providing customers with the highest quality services, assist in the discovery and development of new drugs and medical devices, help in the study of disease and ultimately lead to the improvement of human health. Investors of Charles River Laboratories International are now being urged to take action before the deadline set by The Schall Law Firm. Specifically, the investigation relates to the company’s financial and accounting practices and its reporting to investors.
Price History
On Wednesday, CRL stock opened at $194.5 and closed at $193.4, down by 1.4% from its previous closing price of 196.0. The Schall Law firm is investigating potential claims on behalf of investors of CRL regarding possible violations of federal securities laws. The investigation focuses on certain statements made by CRL concerning its business, operations, and prospects.
Those with information or investment losses related to this investigation are encouraged to contact The Schall Law Firm for a free consultation. Further information can be found on the firm’s website. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for CRL. More…
| Total Revenues | Net Income | Net Margin |
| 4.09k | 496.33 | 12.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for CRL. More…
| Operations | Investing | Financing |
| 626.39 | -678.53 | -3.87 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for CRL. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 7.7k | 4.54k | 60.74 |
Key Ratios Snapshot
Some of the financial key ratios for CRL are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 14.5% | 21.3% | 17.8% |
| FCF Margin | ROE | ROA |
| 6.7% | 14.9% | 5.9% |
Analysis – CRL Intrinsic Stock Value
At GoodWhale, we specialize in analyzing the fundamentals of stocks and helping investors make sound decisions. Our proprietary Valuation Line is a feature that allows investors to gain an understanding of a company’s intrinsic value. Currently, CHARLES RIVER LABORATORIES INTERNATIONAL stock is traded at $193.4, which is 39.5% lower than its estimated value. This suggests that investors may wish to consider adding this stock to their portfolio, as it is currently undervalued. We recommend further research into the company’s fundamentals and performance, to assess its risk and potential reward. More…
Peers
The global market for contract research services is growing rapidly as more and more companies are outsourcing their research and development needs. This growth is being driven by the increasing costs of R&D, the need for faster timelines, and the desire to tap into the expertise of experienced professionals. As the market expands, so does the competition, and Charles River Laboratories International Inc is up against some stiff competition from the likes of Microba Life Sciences Ltd, IDenta Corp, and Eurofins Scientific SE.
– Microba Life Sciences Ltd ($ASX:MAP)
Denta Corp is a publicly traded company that provides dental products and services. The company has a market capitalization of 1.5 million as of 2022 and a return on equity of -10.42%. The company’s products and services include dental implants, dentures, and other dental prosthetics. Denta Corp also provides dental education and training services. The company was founded in 2006 and is headquartered in New York, New York.
– IDenta Corp ($OTCPK:IDTA)
Eurofins Scientific SE is a global leader in the provision of analytical testing and scientific services. The company has a market capitalization of 13.54 billion as of 2022 and a return on equity of 12.32%. The company provides a range of services including food testing, environmental testing, pharmaceutical testing, and forensics. Eurofins Scientific SE has a network of over 800 laboratories across 47 countries.
Summary
Charles River Laboratories International, Inc. (NYSE: CRL) investors are encouraged to contact The Schall Law Firm to discuss their legal rights and options. The lawsuit alleges that Charles River Laboratories International Inc. made false and/or misleading statements and/or failed to disclose material information about its business, operations, financial performance, and prospects. Specifically, the lawsuit contends that the company failed to disclose that its top-line revenue was overstated due to improper accounting methodologies, that the company lacked adequate internal controls over financial reporting, and that as a result of the foregoing, defendants’ statements about Charles River Laboratories’ business, operations, and prospects were false and misleading and/or lacked a reasonable basis. Consequently, investors may have suffered significant losses and damages caused by the company’s wrongful acts.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
